Novo Nordisk Reports Etavopivat Phase 3 Breakthrough
Bagsværd, Denmark, April 20, 2026 Novo Nordisk has announced breakthrough Phase 3 clinical trial results for etavopivat, a first-in-class...
Phase 3
Advertisement
Alkermes Reports Strong Phase 2 Data for Narcolepsy Drug
DUBLIN, April 16, 2026 Alkermes plc has announced new data from its Vibrance-1 Phase 2 clinical study of alixorexton,...
AIM ImmunoTech Advances Ampligen Phase 3 Cancer Trial
OCALA, Fla., April 16, 2026 AIM ImmunoTech Inc. has announced significant progress in its oncology pipeline, entering a pivotal...
Organon VTAMA Cream Gains Strong AAD Guideline Support
Jersey City, New Jersey, U.S. | April 15, 2026 Organon has announced that its VTAMA® (tapinarof) cream, 1% has...
Advertisement
